Iantrek Reports 37% Eye Pressure Drop in Canaloplasty Trial
Six-month data show bio-reinforced canaloplasty cuts intraocular pressure by 37%; cyclodialysis findings head to AAO 2026.
Iantrek, a company focused on bio-interventional ophthalmic surgery, has released six-month clinical data showing a 37% reduction in intraocular pressure (IOP) from a new bio-reinforced canaloplasty procedure, the company announced. The results represent a significant early benchmark for the company's approach to treating glaucoma through surgical intervention targeting the trabecular outflow pathway.
Bio-reinforced canaloplasty is designed to restore the eye's natural drainage system, and the six-month IOP reduction figure positions the technique as a potentially meaningful advance over existing minimally invasive glaucoma surgeries. Sustained pressure lowering is a central clinical goal in glaucoma management, as elevated IOP is the primary modifiable risk factor for optic nerve damage and vision loss.
Read more X4 Pharmaceuticals Lands $150M Debt Facility With K2 HealthVentures →
In addition to the canaloplasty data, Iantrek announced that new findings on bio-reinforced cyclodialysis — a procedure targeting the uveoscleral outflow pathway — will be presented at the American Academy of Ophthalmology annual meeting in 2026. The dual-pathway strategy suggests the company is building a clinical evidence base across more than one surgical approach to pressure reduction.
The AAO annual meeting is one of the most prominent venues for ophthalmic research, and a presentation there typically signals a company's readiness to engage the broader specialist community with its data. Iantrek's decision to present cyclodialysis results at that forum indicates advancing confidence in the procedure's early outcomes, though longer-term and larger-scale data have yet to be disclosed publicly.
Continue reading at GlobeNewswire - Industry News on Financial Services.
